Abstract

The immunomodulation of macrophages against cancer has become a promising avenue for therapy. However, activation of macrophages during antitumour immunotherapy faces two major challenges. First, cancer cells avoid phagocytosis by macrophages by expressing “don’t eat me” signals on the surface. Next, tumour cells release colony-stimulating factors that drive the polarisation of tumour-associated macrophages (TAMs) into M2 cells that support tumour growth. Biomimetic nanotechnology has emerged as a potential tool for delivery of diverse drugs. Herein, we summarise the use of biomimetic nanoparticles that target the repolarisation and phagocytosis of TAMs. Because biomimetic nanoparticles, together with modification technologies, display superiority in prolonged circulation, good biocompatibility, weak immunogenicity and high targeting specificity compared to conventional nanoparticles, we emphasis various biomimetic nanomaterials that mechanistically utilise the repolarisation or phagocytosis of TAMs.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.